Standout Papers

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in ... 2005 2026 2012 2019 1.1k
  1. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. (2005)
    Michel Marty, Francesco Cognetti et al. IRIS UNIMORE (University of Modena and Reggio Emilia)

Immediate Impact

4 by Nobel laureates 9 from Science/Nature 87 standout
Sub-graph 1 of 17

Citing Papers

Natural killer cell therapies
2024 StandoutNature
N6-methyladenosine regulated FGFR4 attenuates ferroptotic cell death in recalcitrant HER2-positive breast cancer
2022 Standout
1 intermediate paper

Works of Antonio Antón being referenced

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.
2005 Standout
Randomized Phase II Trial of the Efficacy and Safety of Trastuzumab Combined With Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Administered As First-Line Treatment: The M77001 Study Group
2005

Author Peers

Author Last Decade Papers Cites
Antonio Antón 1201 400 343 506 37 1.5k
Wei Shen 844 455 314 394 42 2.1k
N. Davidson 1274 348 264 284 41 1.9k
Stefania Salvagni 1189 515 177 303 46 1.7k
Daniel Shasha 776 626 158 270 54 1.7k
Christel Fontaine 678 347 172 484 71 1.4k
Vernon Harvey 1241 344 467 303 44 1.8k
François Eschwège 569 840 249 577 35 2.0k
Janice Lu 800 382 298 254 49 1.3k
R I Swift 1281 361 194 537 31 2.0k
John Hohneker 1435 484 259 169 39 1.9k

All Works

Loading papers...

Rankless by CCL
2026